| Literature DB >> 29141224 |
Bradley Garman1, Ioannis N Anastopoulos1, Clemens Krepler2, Patricia Brafford2, Katrin Sproesser2, Yuchao Jiang3, Bradley Wubbenhorst1, Ravi Amaravadi4, Joseph Bennett5, Marilda Beqiri2, David Elder6, Keith T Flaherty7, Dennie T Frederick7, Tara C Gangadhar4, Michael Guarino5, David Hoon8, Giorgos Karakousis9, Qin Liu2, Nandita Mitra10, Nicholas J Petrelli5, Lynn Schuchter4, Batool Shannan2, Carol L Shields11, Jennifer Wargo12, Brandon Wenz1, Melissa A Wilson13, Min Xiao2, Wei Xu14, Xaiowei Xu6, Xiangfan Yin2, Nancy R Zhang3, Michael A Davies15, Meenhard Herlyn2, Katherine L Nathanson16.
Abstract
Tumor-sequencing studies have revealed the widespread genetic diversity of melanoma. Sequencing of 108 genes previously implicated in melanomagenesis was performed on 462 patient-derived xenografts (PDXs), cell lines, and tumors to identify mutational and copy number aberrations. Samples came from 371 unique individuals: 263 were naive to treatment, and 108 were previously treated with targeted therapy (34), immunotherapy (54), or both (20). Models of all previously reported major melanoma subtypes (BRAF, NRAS, NF1, KIT, and WT/WT/WT) were identified. Multiple minor melanoma subtypes were also recapitulated, including melanomas with multiple activating mutations in the MAPK-signaling pathway and chromatin-remodeling gene mutations. These well-characterized melanoma PDXs and cell lines can be used not only as reagents for a large array of biological studies but also as pre-clinical models to facilitate drug development.Entities:
Keywords: cell lines; massively parallel sequencing; melanoma; patient-derived xenografts
Mesh：
Year: 2017 PMID： 29141224 PMCID： PMC5709812 DOI： 10.1016/j.celrep.2017.10.052
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423